Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants

Pharmacological Research

Volumn 63, Issue 1, 2011, Pages 1-7

  Stojanova, Jana ^a,b   Caillard, Sophie ^c   Rousseau, Annick ^a,b   Marquet, Pierre ^a,b  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Immunosuppressants; Lymphoproliferative disorders; Pharmacogenetics; Risk factors; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOKINE RECEPTOR; EVEROLIMUS; FRESENIUS; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AGE DISTRIBUTION; B CELL LYMPHOMA; CANCER RISK; CARCINOGENESIS; CYTOKINE RESPONSE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; EPSTEIN BARR VIRUS INFECTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS A; HEPATITIS B; HEPATITIS C; HLA MATCHING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; ONSET AGE; ORGAN TRANSPLANTATION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN CANCER; T CELL DEPLETION; T CELL LYMPHOMA; TREATMENT DURATION; VIRUS PATHOGENESIS;

ANIMALS; CYTOKINES; EPSTEIN-BARR VIRUS INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79151474679     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.10.016     Document Type: Review

References (69)

1. G. Opelzand, and B. Dohler Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 222 230
2. H. Tran, J. Nourse, S. Hall, M. Green, L. Griffiths, and M.K. Gandhi Immunodeficiency-associated lymphomas Blood Rev 22 2008 261 281
3. N.L. Harris, J.A. Ferry, and S.H. Swerdlow Posttransplant lymphoproliferative disorders: summary of society for hematopathology workshop Semin Diagn Pathol 14 1997 8 14
4. S. Caillard, V. Dharnidharka, L. Agodoa, E. Bohen, and K. Abbott Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression Transplantation 80 2005 1233 1243
5. R.J. Faull, P. Hollett, and S.P. McDonald Lymphoproliferative disease after renal transplantation in Australia and New Zealand Transplantation 80 2005 193 197
6. J. Brewin, C. Mancao, K. Straathof, H. Karlsson, S. Samarasinghe, and P.J. Amrolia Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease Blood 114 2009 4792 4803
7. B. De Angelis, G. Dotti, C. Quintarelli, L.E. Huye, L. Zhang, and M. Zhang Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) Blood 114 2009 4784 4791
8. U. Allenand, and J. Preiksaitis Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients Am J Transplant 9 Suppl 4 2009 S87 S96
9. G. Opelz, V. Daniel, C. Naujokat, and B. Dohler Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma Transplantation 88 2009 962 967
10. M.T. van Leeuwen, A.E. Grulich, A.C. Webster, M.R. McCredie, J.H. Stewart, and S.P. McDonald Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation Blood 114 2009 630 637
11. V. Leblond, F. Davi, F. Charlotte, R. Dorent, M.O. Bitker, and L. Sutton Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16 1998 2052 2059
12. A.L. Snowand, and O.M. Martinez Epstein-Barr virus: evasive maneuvers in the development of PTLD Am J Transplant 7 2007 271 277
13. R. Dolcetti B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders Autoimmun Rev 7 2007 96 101
14. D. Capello, D. Rossi, and G. Gaidano Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis Hematol Oncol 23 2005 61 67
15. A. Duval, M. Raphael, C. Brennetot, H. Poirel, O. Buhard, and A. Aubry The mutator pathway is a feature of immunodeficiency-related lymphomas Proc Natl Acad Sci USA 101 2004 5002 5007
16. S.M. Cockfield Identifying the patient at risk for post-transplant lymphoproliferative disorder Transpl Infect Dis 3 2001 70 78
17. N.A. Bakker, G.W. van Imhoff, E.A. Verschuuren, and W.J. van Son Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation Transpl Int 20 2007 207 218
18. D. Capello, S. Rasi, P. Oreste, S. Veronese, M. Cerri, and E. Ravelli Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients J Pathol 218 2009 478 486
19. S. Caillard, E. Pencreach, L. Braun, L. Marcellin, M.L. Jaegle, and P. Wolf Simultaneous development of lymphoma in recipients of renal transplants from a single donor: donor origin confirmed by human leukocyte antigen staining and microsatellite analysis Transplantation 79 2005 79 84
20. B. Petit, Y. Le Meur, A. Jaccard, F. Paraf, C.L. Robert, and D. Bordessoule Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation Transplantation 73 2002 265 271
21. A. Chadburn, N. Suciu-Foca, E. Cesarman, E. Reed, R.E. Michler, and D.M. Knowles Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin Am J Pathol 147 1995 1862 1870
22. M.L. Gulley, L.J. Swinnen, K.T. Plaisance Jr., C. Schnell, T.M. Grogan, and B.G. Schneider Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy Transplantation 76 2003 959 964
23. M.R. Peterson, S.C. Emery, G.L. Yung, E. Masliah, and E.S. Yi Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder following lung transplantation is more commonly of host origin Arch Pathol Lab Med 130 2006 176 180
24. C. Doria, I.R. Marino, V.L. Scott, R. Jaffe, M.I. Minervini, and A. Zajko Posttransplant lymphoproliferative disorders presenting at sites of previous surgical intervention Transplantation 75 2003 1066 1069
25. M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto, and M. Lagman Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530 534
26. M. Suthanthiran, M. Hojo, M. Maluccio, D.J. Boffa, and F.L. Luan Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy Trans Am Clin Climatol Assoc 120 2009 369 388
27. M. Guba, C. Graeb, K.W. Jauch, and E.K. Geissler Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation Transplantation 77 2004 1777 1782
28. G. Tosato, J. Teruya-Feldstein, J. Setsuda, S.E. Pike, K.D. Jones, and E.S. Jaffe Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD Springer Semin Immunopathol 20 1998 405 423
29. K.A. McAulay, T. Haque, and D.H. Crawford Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease Br J Cancer 101 2009 1019 1027
30. A.M. VanBuskirk, V. Malik, D. Xia, and R.P. Pelletier A gene polymorphism associated with posttransplant lymphoproliferative disorder Transplant Proc 33 2001 1834
31. J.E. Dierksheide, R.A. Baiocchi, A.K. Ferketich, S. Roychowdhury, R.P. Pelletier, and C.F. Eisenbeis IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice Blood 105 2005 1558 1565
32. N. Babel, A. Vergopoulos, R.U. Trappe, S. Oertel, M.H. Hammer, and S. Karaivanov Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients Transplantation 84 2007 387 391
33. M. Stern, G. Opelz, B. Dohler, and C. Hess Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma Blood 115 2010 3960 3965
34. T.C. Lee, B. Savoldo, N.R. Barshes, C.M. Rooney, H.E. Heslop, and A.P. Gee Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients Clin Transplant 20 2006 389 393
35. R.V. Thomas, K. McAulay, C. Higgins, G. Wilkie, and D.H. Crawford Interferon gamma (IFN-gamma) polymorphism in posttransplantation lymphoproliferative disease Blood 106 2005 1502 1503 [author reply 1503]
36. G. Opelz, V. Daniel, C. Naujokat, H. Fickenscher, and B. Dohler Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis Lancet Oncol 8 2007 212 218
37. W.S. Cherikh, H.M. Kauffman, M.A. McBride, J. Maghirang, L.J. Swinnen, and D.W. Hanto Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation Transplantation 76 2003 1289 1293
38. A.D. Kirk, W.S. Cherikh, M. Ring, G. Burke, D. Kaufman, and S.J. Knechtle Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab Am J Transplant 7 2007 2619 2625
39. D.P. Funch, A.M. Walker, G. Schneider, N.J. Ziyadeh, and M.D. Pescovitz Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients Am J Transplant 5 2005 2894 2900
40. R.T. Bustami, A.O. Ojo, R.A. Wolfe, R.M. Merion, W.M. Bennett, and S.V. McDiarmid Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients Am J Transplant 4 2004 87 93
41. P. Burra, A. Buda, U. Livi, P. Rigotti, G. Zanus, and F. Calabrese Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 18 2006 1065 1070
42. C. Duvoux, G.P. Pageaux, C. Vanlemmens, F. Roudot-Thoraval, A.L. Vincens-Rolland, and C. Hezode Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients Transplantation 74 2002 1103 1109
43. N.N. Zein, R.G. Perez, and R.H. Wiesner Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation Hepatology 31 2000 808 809
44. L.M. Morton, O. Landgren, N. Chatterjee, D. Castenson, R. Parsons, and R.N. Hoover Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients Blood 110 2007 4599 4605
45. N.A. Bakker, G.W. van Imhoff, E.A. Verschuuren, W.J. van Son, J.J. van der Heide, and S.P. Lems HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical Transplantation 80 2005 595 599
46. G. Opelzand, and B. Dohler Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation Transplantation 89 2010 567 572
47. G. Opelzand, and R. Henderson Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients Lancet 342 1993 1514 1516
48. G. Opelz, C. Naujokat, V. Daniel, P. Terness, and B. Dohler Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients Transplantation 81 2006 1227 1233
49. L.J. Swinnen, M.R. Costanzo-Nordin, S.G. Fisher, E.J. O'Sullivan, M.R. Johnson, and A.L. Heroux Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients N Engl J Med 323 1990 1723 1728
50. P.R. Beatty, S.M. Krams, C.O. Esquivel, and O.M. Martinez Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines Transplantation 65 1998 1248 1255
51. A. Gutierrez-Dalmauand, and J.M. Campistol Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review Drugs 67 2007 1167 1198
52. G. Vegso, A. Sebestyen, S. Paku, G. Barna, M. Hajdu, and M. Toth Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas Leuk Res 31 2007 1003 1008
53. D.P. Funch, H.H. Ko, J. Travasso, J. Brady, C.E. Kew 2nd, and M.A. Nalesnik Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil Transplantation 80 2005 1174 1180
54. R. Robson, J.M. Cecka, G. Opelz, M. Budde, and S. Sacks Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil Am J Transplant 5 2005 2954 2960
55. J.M. Campistol, J. Eris, R. Oberbauer, P. Friend, B. Hutchison, and J.M. Morales Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation J Am Soc Nephrol 17 2006 581 589
56. H.M. Kauffman, W.S. Cherikh, Y. Cheng, D.W. Hanto, and B.D. Kahan Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883 889
57. B.D. Kahan, Y.K. Yakupoglu, L. Schoenberg, R.J. Knight, S.M. Katz, and D. Lai Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients Transplantation 80 2005 749 758
58. M. Majewski, M. Korecka, P. Kossev, S. Li, J. Goldman, and J. Moore The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders Proc Natl Acad Sci USA 97 2000 4285 4290
59. R.R. Nepomuceno, C.E. Balatoni, Y. Natkunam, A.L. Snow, S.M. Krams, and O.M. Martinez Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas Cancer Res 63 2003 4472 4480
60. M. Boratynskaand, and D. Smolska Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders Transpl Int 21 2008 605 608
61. J. Pascual Post-transplant lymphoproliferative disorder - the potential of proliferation signal inhibitors Nephrol Dial Transplant 22 Suppl 1 2007 i27-35
62. H. Ekberg, H. Tedesco-Silva, A. Demirbas, S. Vitko, B. Nashan, and A. Gurkan Reduced exposure to calcineurin inhibitors in renal transplantation N Engl J Med 357 2007 2562 2575
63. F. Vincenti, B. Charpentier, Y. Vanrenterghem, L. Rostaing, B. Bresnahan, and P. Darji A phase iii study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study) Am J Transpl 10 2010 547 557
64. A. Durrbach, J.M. Pestana, T. Pearson, F. Vincenti, V.D. Garcia, and J. Campistol A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study) Am J Transpl 10 2010 547 557
65. J. McCann Lowering immune suppression drugs post-transplant may cut cancer risk J Natl Cancer Inst 95 2003 848 849
66. R.A. McDonald, J.M. Smith, M. Ho, R. Lindblad, D. Ikle, and P. Grimm Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids Am J Transplant 8 2008 984 989
67. J. Dantal, M. Hourmant, D. Cantarovich, M. Giral, G. Blancho, and B. Dreno Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens Lancet 351 1998 623 628 (Pubitemid 28098444)
68. C. Sommerer, W. Hartschuh, A. Enk, S. Meuer, M. Zeier, and T. Giese Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients Clin Transplant 22 2008 549 554
69. T. Giese, C. Sommerer, M. Zeier, and S. Meuer Monitoring immunosuppression with measures of NFAT decreases cancer incidence Clin Immunol 132 2009 305 311